Gain Therapeutics 将来の成長

Future 基準チェック /06

Gain Therapeuticsの収益と利益はそれぞれ年間2.2%と18.9%減少すると予測されていますが、EPS は年間11.6% 減少すると予測されています。

主要情報

-18.9%

収益成長率

-11.6%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	-2.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	25 Nov 2024

今後の成長に関する最新情報

Recent updates

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 29

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 12

Gain Therapeutics appoints CEO

Sep 20

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Oct 27

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Aug 19

Gain Therapeutics EPS misses by $0.29

May 10

業績と収益の成長予測

NasdaqGM:GANX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-33	N/A	N/A	2
12/31/2025	0	-25	N/A	N/A	4
12/31/2024	N/A	-21	N/A	N/A	5
9/30/2024	N/A	-21	-21	-21	N/A
6/30/2024	N/A	-22	-19	-19	N/A
3/31/2024	N/A	-21	-18	-18	N/A
12/31/2023	0	-22	-19	-19	N/A
9/30/2023	0	-22	-17	-17	N/A
6/30/2023	0	-22	-17	-16	N/A
3/31/2023	0	-19	-17	-16	N/A
12/31/2022	0	-18	-15	-15	N/A
9/30/2022	0	-16	-15	-15	N/A
6/30/2022	0	-16	-14	-14	N/A
3/31/2022	0	-15	-12	-12	N/A
12/31/2021	0	-14	-12	-12	N/A
9/30/2021	0	-12	-10	-10	N/A
6/30/2021	0	-8	-8	-8	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-4	-3	-3	N/A
9/30/2020	N/A	-3	-2	-2	N/A
12/31/2019	N/A	-2	-2	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GANX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GANX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: GANX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GANXの収益は今後 3 年間で減少すると予想されています (年間-2.2% )。

高い収益成長: GANXの収益は今後 3 年間で減少すると予測されています (年間-2.2% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GANXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Gain Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$0.97 loss, revenue downgraded

Consensus revenue estimates fall by 40%

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus revenue estimates fall by 16%

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Recent updates

Gain Therapeutics, Inc. Announces Presentation of Preclinical Data for the Product Candidate, GT-02287

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics, Inc. Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics, Inc. Announces CEO Changes

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.999898 million.

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Consensus EPS estimates upgraded to US$0.97 loss, revenue downgraded

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Consensus revenue estimates fall by 40%

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

New major risk - Financial position

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Consensus revenue estimates decrease by 11%, EPS upgraded

Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has filed a Follow-on Equity Offering.

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.62 loss per share (vs US$0.43 loss in 2Q 2022)

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Gain Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

High number of new and inexperienced directors

Gain Therapeutics, Inc. Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

Gain Therapeutics Announces Chief Executive Officer Changes

Gain Therapeutics appoints CEO

Gain Therapeutics, Inc. Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

Price target decreased to US$19.25

Consensus forecasts updated

Consensus forecasts updated

Gain Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$22.00

High number of new and inexperienced directors

Price target decreased to US$22.00

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid

Gain Therapeutics Presents Preclinical Data on Its Structurally Targeted Allosteric Regulators in Gba1 Gaucher Disease At the Worldsymposium 2022

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-Derived Ipsc Study Evaluating Star Compounds as A Treatment for Gaucher and Parkinson’S Disease

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Gain Therapeutics EPS misses by $0.29

Gain Therapeutics, Inc. Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related a-synucleopathies at the XXVI IAPRD World Congress

Gain Therapeutics, Inc. has completed an IPO in the amount of $40.000004 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘